Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
Vaccines form an important part of the combat against the current COVID-19 health crisis. Getting a range of effective vaccines to the market quickly will be essential if we are ever to “return to normal”. Following the landmark moment of a first COVID-19 vaccine approval in December 2020, this article explores how an accelerated regulatory pathway using challenge studies could speed up time to market for further COVID-19 vaccines.